Immunotherapy with mycobacterium vaccae in the treatment of mycobacterial disease

Journal of Infection

Volumn 39, Issue 3, 1999, Pages 179-182

  Stanford, J L ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTHERAPY; MYCOBACTERIOSIS; MYCOBACTERIUM VACCAE; SHORT SURVEY;

EID: 0033390564     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(99)90044-0     Document Type: Review

References (22)

1. Shield MJ, Stanford JL, Garbajosa G, Draper P, Rees RJW. The epidemiological evaluation in Burma, of the skin test reagent LRA6: a cell-free extract from armadilloderived Mycobacterium leprae. Part 1: Leprosy patients. International Journal of Leprosy 1982; 50: 436-445.
2. Grange JM. The mystery of the mycobacterial persister. Tubercle and Lung Disease. 1992; 73: 249-251.
3. Romanus V, Hallander HO, Wahlen P, Olinder-Nielsen AM, Magnuson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76: 300-310.
4. Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infection and Immunity 1997; 65: 3317-3327.
5. Stanford JL, Paul RC. 1973. A preliminary report on some studies of environmental mycobacteria. Annals de la Societe Belge de Medecine Tropicale 1973; 53: 389-393.
6. Stanford JL, Shield MJ, Rook GAW. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981; 62: 55-62.
7. Stanford JL, Rook GAW Environmental mycobacteria and immunisation with BCG. In: Medical microbiology 1983; 2: 43-69. Easmon CSF, Jeljaszewicz J, eds Academic Press, London.
8. Stanford JL, Stanford CA, Ghazi Saidi K et al. Vaccination and skin test studies on the children of leprosy patients. International Journal of Leprosy 1989; 57: 38-44.
9. Stanford JL, Terencio de las Aguas J, Torres P, Gervasioni BO, Ravioli R. Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Cooperation Papers 1987; 7: Proceedings of the Fourth European Leprosy Symposium: 201-206.
10. Bahr GM, Shaaban MA, Gabriel M Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 1990; 71: 259-266.
11. Stanford JL, Stanford CA, Rook GAW, Grange JM. Immunotherapy for tuberculosis - investigative and practical aspects. Clinical Immunotherapy 1994; 1: 430-440.
12. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae 1) In the treatment of newly diagnosed pulmonary tuberculosis in Romania. Respiratory Medicine 1997; 91: 13-19.
13. Dlugovitzky D, Bottasso O, Dominino JC et al. Clinical and serological studies of tuberculosis patients receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respiratory Medicine 1999; 33: 557-562.
14. Onyebujoh P, Abdulmumini T, Robinson S, Rook GAW, Stanford JL. Immunotherapy for tuberculosis in African conditions. Respiratory Medicine 1995; 89: 199-207.
15. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL, Wallis RS, Hirsch CS, Wolski K, Foulds J, Mugwera RD, Ellner JJ. A controlled trial of heat-killed Mycobacterium vaccae as a therapeutic vaccine in HIV non-infected Ugandans with pulmonary tuberculosis: microbiologic, radiographic and immunologic activity. 1999 (submitted).
16. Durban Immunotherapy Trial Group. Randomised controlled trial of immunotherapy with Mycobacterium vaccae in newly diagnosed pulmonary tuberculosis patients in South Africa. Lancet 1999; 354: 116-119.
17. Mayo REP. Mycobacterium vaccae immunotherapy for tuberculosis in rural KwaZulu, South Africa. MD thesis, university of London. 1999 (submitted).
18. Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis, (letter) Lancet 1992; 340: 360-361.
19. Corlan E, Marica C, Macavej C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae 2) In the treatment of chronic or relapsed tuberculosis in Romania. Respiratory Medicine 1997; 91: 21-29.
20. Stanford JL. The history and future of vaccination and Immunotherapy for leprosy. Tropical and Geographical Medicine 1994; 46: 93-107.
21. Skinner MA, Yuan S, Prestdge R, Chuk D, Watson JD, Tan PLJ. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculsis, Infection and Immunity 1997; 65: 4525-4530.
22. Rook GAW, Onyebujoh P, Wilkins E, Ho Minh Ly, Al Attiyah R, Bahr GM, Corrah T, Hernandez-Munoz H, Stanford JL. A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 1994; 81: 149-154.